STRS Ohio’s Relmada Therapeutics RLMD Stock Holding History

STRS Ohio’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-6,100	Closed	-$164K	–	2246
2022 Q1	$164K	Hold	6,100	–	–	﹤0.01%	1756
2021 Q4	$137K	Hold	6,100	–	–	﹤0.01%	1831
2021 Q3	$159K	Buy	6,100 +900	+17%	+$24.1K	﹤0.01%	1832
2021 Q2	$166K	Buy	+5,200	New	+$181K	﹤0.01%	1866
2020 Q3	–	Sell	-3,600	Closed	-$161K	–	2265
2020 Q2	$161K	Buy	+3,600	New	+$152K	﹤0.01%	1687

Other funds holding RLMD

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

STRS Ohio's RLMD Position: Q2 2022 in Review

STRS Ohio sold out of Relmada Therapeutics (RLMD) in Q2 2022, closing a stake of 6,100 shares — an estimated $164K sold.

STRS Ohio first reported a position in RLMD in Q2 2020 and held it in 5 quarters. The position peaked at $166K in Q2 2021. 113 funds tracked by Wall St. Rank hold RLMD as of Q2 2022.

STRS Ohio reported no remaining Relmada Therapeutics position as of Q2 2022 after selling out during the quarter.
STRS Ohio sold 6,100 Relmada Therapeutics shares in Q2 2022, an estimated $164K.
STRS Ohio first reported a position in Relmada Therapeutics in Q2 2020 and held it in 5 quarters.
STRS Ohio's Relmada Therapeutics position peaked at $166K in Q2 2021.
113 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2022.

Based on STRS Ohio's 13F filing for Q2 2022, filed 25 Jul 2022.